{"gene":"IP6K3","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":2001,"finding":"IP6K3 (InsP6K3) was identified as a third inositol hexakisphosphate kinase that converts IP6 to InsP7 (diphosphoinositol pentakisphosphate). IP6K3 has a smaller mass (46 kDa) and more basic character than IP6K1/2, and its intracellular disposition was determined by fractionation: IP6K3 predominates in the cytoplasm, distinguishing it from the exclusively nuclear IP6K2 and the dual nuclear/cytosolic IP6K1.","method":"Enzyme activity assay (in vitro IP7 production), cellular fractionation, sequence analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic characterization combined with subcellular fractionation; foundational paper replicated in subsequent work","pmids":["11502751"],"is_preprint":false},{"year":2015,"finding":"IP6K3 is highly concentrated in cerebellar Purkinje cells and physically interacts with the cytoskeletal proteins adducin and spectrin. In IP6K3-null mice, the adducin–spectrin interaction is perturbed, leading to abnormalities in Purkinje cell structure and synapse number, and deficits in motor learning and coordination.","method":"Co-immunoprecipitation (IP6K3 binding to adducin and spectrin), IP6K3 knockout mouse phenotype (cerebellar morphology, synapse counting, motor behavior tests)","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus clean KO with defined structural and behavioral phenotypes in multiple assays","pmids":["26245967"],"is_preprint":false},{"year":2019,"finding":"IP6K3 is enriched at the leading edge of migrating cells and physically associates with dynein intermediate chain 2 (DIC2). DIC2 and IP6K3 are recruited interdependently to the leading edge, where they cooperate to promote focal adhesion turnover. Deletion of IP6K3 causes defects in cell motility and neuronal dendritic growth, leading to brain malformations.","method":"Immunofluorescence microscopy, total internal reflection fluorescence (TIRF) microscopy, Co-immunoprecipitation (IP6K3–DIC2 interaction), IP6K3 knockout cells/mice with focal adhesion and motility assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, live TIRF imaging, and clean KO with multiple defined cellular and developmental phenotypes","pmids":["30718399"],"is_preprint":false},{"year":2016,"finding":"Genetic deletion of Ip6k3 in mice results in lower blood glucose, reduced circulating insulin, decreased fat mass, lower body weight, increased plasma lactate, enhanced glucose tolerance, improved insulin sensitivity, reduced muscle Pdk4 expression, and extended animal lifespan with concomitant reduced phosphorylation of S6 ribosomal protein in the heart, establishing IP6K3 as a regulator of metabolic homeostasis and longevity.","method":"Ip6k3 knockout mouse metabolic phenotyping (glucose tolerance test, insulin tolerance test, body composition, plasma metabolites, S6 phosphorylation by western blot)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with multiple metabolic readouts in a single lab; no independent replication reported","pmids":["27577108"],"is_preprint":false},{"year":2022,"finding":"IP6K3 knockout reduces the size of the readily releasable pool (RRP) of synaptic vesicles containing both VGLUT1 and VGLUT2, and decreases synaptic facilitation at CA1 hippocampal Schaffer collateral synapses, whereas IP6K1 KO has the opposite effect on exocytosis. Both IP6K1 and IP6K3 KO similarly enhance endocytosis of VGLUT2-pHluorin after intense stimulation. IP6K3 is expressed in axons.","method":"IP6K3 knockout mice, live-cell imaging with pHluorin optical reporters (VGLUT1-pH, VGLUT2-pH), electrophysiology (CA1 field recordings), shRNA knockdown, pharmacological inhibition","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO plus electrophysiology and live imaging; single lab but multiple orthogonal approaches","pmids":["35936490"],"is_preprint":false},{"year":2012,"finding":"The nuclear protein PA1 represses glucocorticoid receptor (GR)-mediated induction of the endogenous IP6K3 gene by blocking GR binding to the IP6K3 promoter, as demonstrated by ChIP and re-ChIP experiments, placing IP6K3 as a direct transcriptional target of GR regulated by the cofactor PA1.","method":"ChIP and re-ChIP at the IP6K3 promoter, luciferase reporter assays, endogenous gene expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP at endogenous locus in a single lab; establishes transcriptional regulation mechanism","pmids":["23161582"],"is_preprint":false},{"year":2016,"finding":"A SNP (rs28607030) in the 5'-flanking promoter region of the IP6K3 gene affects IP6K3 promoter activity, with the G allele showing increased transcriptional activity as measured by luciferase assay, functionally linking promoter variation to altered IP6K3 expression levels.","method":"Luciferase reporter assay of IP6K3 promoter SNP variants","journal":"Biochimica et biophysica acta","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single luciferase assay in a single lab; no additional mechanistic follow-up","pmids":["27345265"],"is_preprint":false},{"year":2026,"finding":"Silencing of IP6K3 in calcifying primary human aortic vascular smooth muscle cells (VSMCs) produces some anti-calcific effects, suggesting a role in phosphate-induced VSMC calcification; however, IP6K3 mRNA expression was not modified under pro-calcific conditions, distinguishing IP6K3 from IP6K1/2 in this context.","method":"siRNA knockdown of IP6K3 in primary human aortic VSMCs, pro-calcific marker expression and calcification assays","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single knockdown experiment, single lab, partial mechanistic characterization without pathway placement for IP6K3 specifically","pmids":["41683831"],"is_preprint":false}],"current_model":"IP6K3 is a cytoplasmic inositol hexakisphosphate kinase that converts IP6 to the inositol pyrophosphate 5-IP7; in the brain it is highly enriched in cerebellar Purkinje cells where it physically interacts with adducin and spectrin to regulate cytoskeletal organization, synapse formation, and motor learning, and at the leading edge of migrating cells it associates with dynein intermediate chain 2 (DIC2) to drive focal adhesion turnover and cell motility; systemically, its genetic deletion in mice improves glucose and lipid metabolism and extends lifespan, while in neurons it additionally controls synaptic vesicle pool size and exocytosis."},"narrative":{"mechanistic_narrative":"IP6K3 is a cytoplasmic inositol hexakisphosphate kinase that converts IP6 to the inositol pyrophosphate InsP7, distinguishing it from the nuclear IP6K2 and the dual-localized IP6K1 [PMID:11502751]. Beyond this catalytic role, IP6K3 acts as a cytoskeleton-associated organizer in two distinct cellular contexts: it is enriched in cerebellar Purkinje cells where it physically binds adducin and spectrin, and its loss perturbs the adducin–spectrin interaction, distorting Purkinje cell structure and synapse number and impairing motor learning and coordination [PMID:26245967]; and it concentrates at the leading edge of migrating cells where it associates interdependently with dynein intermediate chain 2 (DIC2) to drive focal adhesion turnover, with loss causing motility defects, impaired dendritic growth, and brain malformations [PMID:30718399]. In neurons it additionally governs synaptic vesicle dynamics, with knockout reducing the readily releasable vesicle pool and synaptic facilitation at hippocampal Schaffer collateral synapses [PMID:35936490]. Systemically, genetic deletion of Ip6k3 in mice improves glucose tolerance and insulin sensitivity, reduces fat mass, and extends lifespan, alongside reduced cardiac S6 phosphorylation, establishing IP6K3 as a regulator of metabolic homeostasis and longevity [PMID:27577108]. Transcription of IP6K3 is a direct glucocorticoid receptor target repressed by the cofactor PA1, which blocks GR binding to the IP6K3 promoter [PMID:23161582].","teleology":[{"year":2001,"claim":"Established that IP6K3 is a catalytically active third inositol hexakisphosphate kinase with a distinct subcellular distribution, defining it as a separate enzyme rather than a redundant copy of IP6K1/2.","evidence":"In vitro IP7 production assay, cellular fractionation, and sequence analysis","pmids":["11502751"],"confidence":"High","gaps":["No structural model of the catalytic site","Physiological substrate flux and InsP7 targets in vivo not defined","Functional consequence of cytoplasmic localization unresolved at this stage"]},{"year":2012,"claim":"Answered how IP6K3 expression is controlled, showing it is a direct glucocorticoid receptor transcriptional target whose induction is repressed by the cofactor PA1.","evidence":"ChIP and re-ChIP at the endogenous IP6K3 promoter with luciferase reporter assays","pmids":["23161582"],"confidence":"Medium","gaps":["Physiological conditions driving GR-dependent IP6K3 induction unclear","Whether transcriptional regulation links to the metabolic phenotype untested"]},{"year":2015,"claim":"Identified the first physical partners and tissue-specific function of IP6K3, linking it to cytoskeletal organization in cerebellar Purkinje cells and to motor behavior.","evidence":"Reciprocal Co-IP with adducin and spectrin plus knockout mouse cerebellar morphology, synapse counting, and motor behavior assays","pmids":["26245967"],"confidence":"High","gaps":["Whether IP6K3 catalytic activity (InsP7) is required for the adducin–spectrin effect not separated from a scaffolding role","Molecular basis of adducin/spectrin binding undefined"]},{"year":2016,"claim":"Demonstrated that IP6K3 deletion improves systemic metabolism and extends lifespan, positioning IP6K3 as a regulator of metabolic homeostasis and aging.","evidence":"Ip6k3 knockout mouse metabolic phenotyping with glucose/insulin tolerance tests, body composition, plasma metabolites, and cardiac S6 phosphorylation","pmids":["27577108"],"confidence":"Medium","gaps":["No independent replication reported","Tissue responsible for the metabolic/longevity phenotype not pinpointed","Mechanistic link between InsP7 and S6 signaling not established"]},{"year":2016,"claim":"Linked a promoter SNP to IP6K3 expression level, providing a candidate basis for inter-individual variation in IP6K3 activity.","evidence":"Luciferase reporter assay comparing IP6K3 promoter SNP (rs28607030) variants","pmids":["27345265"],"confidence":"Low","gaps":["Single luciferase assay without endogenous validation","No demonstration of altered IP6K3 protein or phenotype in carriers"]},{"year":2019,"claim":"Revealed a second cytoskeletal function for IP6K3 at the migrating cell leading edge through interdependent recruitment with DIC2 to drive focal adhesion turnover, connecting IP6K3 to motility and brain development.","evidence":"Immunofluorescence and TIRF microscopy, reciprocal Co-IP with DIC2, and knockout cell/mouse focal adhesion, motility, and dendritic growth assays","pmids":["30718399"],"confidence":"High","gaps":["Whether InsP7 production is required for DIC2 cooperation untested","Relationship between the Purkinje adducin/spectrin role and the leading-edge DIC2 role unclear"]},{"year":2022,"claim":"Showed that IP6K3 controls presynaptic vesicle dynamics, reducing the readily releasable pool and synaptic facilitation, with effects opposite to IP6K1 on exocytosis.","evidence":"Knockout mice with pHluorin live imaging (VGLUT1/VGLUT2), CA1 field electrophysiology, shRNA knockdown, and pharmacological inhibition","pmids":["35936490"],"confidence":"Medium","gaps":["Molecular target of IP6K3/InsP7 at the synaptic vesicle cycle unidentified","Basis for opposing IP6K1 vs IP6K3 effects on exocytosis unexplained"]},{"year":2026,"claim":"Implicated IP6K3 in phosphate-induced vascular smooth muscle calcification, distinguishing it from IP6K1/2 by its lack of transcriptional induction under pro-calcific conditions.","evidence":"siRNA knockdown of IP6K3 in primary human aortic VSMCs with calcification assays","pmids":["41683831"],"confidence":"Low","gaps":["Single knockdown experiment without rescue or independent confirmation","Pathway placement of IP6K3 in VSMC calcification not defined"]},{"year":null,"claim":"It remains unresolved whether IP6K3's diverse roles—cytoskeletal scaffolding, focal adhesion turnover, synaptic vesicle control, and metabolic regulation—depend on its InsP7 kinase activity or on activity-independent protein scaffolding, and which downstream effectors of InsP7 mediate each phenotype.","evidence":"","pmids":[],"confidence":"Low","gaps":["No catalytic-dead separation-of-function experiments reported across phenotypes","InsP7-dependent downstream effectors not identified for any tissue context","No structural data to connect catalysis with partner binding"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1,2]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]}],"complexes":[],"partners":["ADD1","SPTBN1","DYNC1I2","PA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96PC2","full_name":"Inositol hexakisphosphate kinase 3","aliases":["Inositol hexaphosphate kinase 3"],"length_aa":410,"mass_kda":46.4,"function":"Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). Converts 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q96PC2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IP6K3","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IP6K3","total_profiled":1310},"omim":[{"mim_id":"606993","title":"INOSITOL HEXAPHOSPHATE KINASE 3; IP6K3","url":"https://www.omim.org/entry/606993"},{"mim_id":"606991","title":"INOSITOL HEXAPHOSPHATE KINASE 1; IP6K1","url":"https://www.omim.org/entry/606991"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"skeletal muscle","ntpm":290.7},{"tissue":"tongue","ntpm":77.8}],"url":"https://www.proteinatlas.org/search/IP6K3"},"hgnc":{"alias_symbol":["INSP6K3"],"prev_symbol":["IHPK3"]},"alphafold":{"accession":"Q96PC2","domains":[{"cath_id":"3.30.470.160","chopping":"17-92_99-105_170-335_360-409","consensus_level":"medium","plddt":89.8939,"start":17,"end":409}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96PC2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96PC2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96PC2-F1-predicted_aligned_error_v6.png","plddt_mean":75.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IP6K3","jax_strain_url":"https://www.jax.org/strain/search?query=IP6K3"},"sequence":{"accession":"Q96PC2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96PC2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96PC2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96PC2"}},"corpus_meta":[{"pmid":"11502751","id":"PMC_11502751","title":"Identification and characterization of a novel inositol hexakisphosphate kinase.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11502751","citation_count":131,"is_preprint":false},{"pmid":"27577108","id":"PMC_27577108","title":"Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27577108","citation_count":60,"is_preprint":false},{"pmid":"26245967","id":"PMC_26245967","title":"Inositol Hexakisphosphate Kinase-3 Regulates the Morphology and Synapse Formation of Cerebellar Purkinje Cells via Spectrin/Adducin.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26245967","citation_count":46,"is_preprint":false},{"pmid":"25441061","id":"PMC_25441061","title":"Molecular mechanism of DNA damage induced by titanium dioxide nanoparticles in toll-like receptor 3 or 4 expressing human hepatocarcinoma cell lines.","date":"2014","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/25441061","citation_count":36,"is_preprint":false},{"pmid":"32204420","id":"PMC_32204420","title":"Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32204420","citation_count":35,"is_preprint":false},{"pmid":"35467861","id":"PMC_35467861","title":"Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35467861","citation_count":24,"is_preprint":false},{"pmid":"27345265","id":"PMC_27345265","title":"Contribution of polymorphic variation of inositol hexakisphosphate kinase 3 (IP6K3) gene promoter to the susceptibility to late onset Alzheimer's disease.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/27345265","citation_count":22,"is_preprint":false},{"pmid":"31185018","id":"PMC_31185018","title":"Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31185018","citation_count":21,"is_preprint":false},{"pmid":"23161582","id":"PMC_23161582","title":"PA1 protein, a new competitive decelerator acting at more than one step to impede glucocorticoid receptor-mediated transactivation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23161582","citation_count":20,"is_preprint":false},{"pmid":"32108446","id":"PMC_32108446","title":"Absence of MyD88 from Skeletal Muscle Protects Female Mice from Inactivity-Induced Adiposity and Insulin Resistance.","date":"2020","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32108446","citation_count":19,"is_preprint":false},{"pmid":"31445853","id":"PMC_31445853","title":"Synthesis and characterization of novel isoform-selective IP6K1 inhibitors.","date":"2019","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31445853","citation_count":17,"is_preprint":false},{"pmid":"33547244","id":"PMC_33547244","title":"Inositol hexakisphosphate kinase-2 determines cellular energy dynamics by regulating creatine kinase-B.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33547244","citation_count":17,"is_preprint":false},{"pmid":"30006360","id":"PMC_30006360","title":"Inositol Hexakisphosphate Kinase-2 in Cerebellar Granule Cells Regulates Purkinje Cells and Motor Coordination via Protein 4.1N.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30006360","citation_count":16,"is_preprint":false},{"pmid":"30718399","id":"PMC_30718399","title":"Inositol hexakisphosphate kinase 3 promotes focal adhesion turnover via interactions with dynein intermediate chain 2.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30718399","citation_count":15,"is_preprint":false},{"pmid":"33497757","id":"PMC_33497757","title":"IP6K3 and IPMK variations in LOAD and longevity: Evidence for a multifaceted signaling network at the crossroad between neurodegeneration and survival.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/33497757","citation_count":13,"is_preprint":false},{"pmid":"38403246","id":"PMC_38403246","title":"Insights into the roles of inositol hexakisphosphate kinase 1 (IP6K1) in mammalian cellular processes.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38403246","citation_count":13,"is_preprint":false},{"pmid":"35936490","id":"PMC_35936490","title":"Inositol hexakisphosphate kinases differentially regulate trafficking of vesicular glutamate transporters 1 and 2.","date":"2022","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35936490","citation_count":12,"is_preprint":false},{"pmid":"37013838","id":"PMC_37013838","title":"Synthesis and biological evaluation of flavonoid-based IP6K2 inhibitors.","date":"2023","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37013838","citation_count":8,"is_preprint":false},{"pmid":"30310084","id":"PMC_30310084","title":"Landscape of alternative splicing in Capra_hircus.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30310084","citation_count":7,"is_preprint":false},{"pmid":"29778423","id":"PMC_29778423","title":"Genetic variants of TREML2 are associated with HLA-B27-positive ankylosing spondylitis.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29778423","citation_count":6,"is_preprint":false},{"pmid":"38116421","id":"PMC_38116421","title":"Fragment-Based Screening Identifies New Quinazolinone-Based Inositol Hexakisphosphate Kinase (IP6K) Inhibitors.","date":"2023","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38116421","citation_count":6,"is_preprint":false},{"pmid":"32676038","id":"PMC_32676038","title":"Monitoring Phytate Hydrolysis Using Serial Blood Sampling and Feather Myo-Inositol Levels in Broilers.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32676038","citation_count":4,"is_preprint":false},{"pmid":"32929655","id":"PMC_32929655","title":"Inositol hexakisphosphate kinase 2 promotes cell death of anterior horn cells in the spinal cord of patients with amyotrophic lateral sclerosis.","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32929655","citation_count":4,"is_preprint":false},{"pmid":"40879991","id":"PMC_40879991","title":"Knockout Mice as an Experimental Model to Study the Biology of Inositol Pyrophosphates.","date":"2025","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/40879991","citation_count":2,"is_preprint":false},{"pmid":"38926963","id":"PMC_38926963","title":"[Whole Exome Sequencing Reveals Gene Mutation Characteristics of Primary Central Nervous System Lymphoma].","date":"2024","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/38926963","citation_count":1,"is_preprint":false},{"pmid":"41683831","id":"PMC_41683831","title":"Role of Inositol Hexakisphosphate Kinases in Vascular Smooth Muscle Cell Calcification.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41683831","citation_count":0,"is_preprint":false},{"pmid":"41387660","id":"PMC_41387660","title":"MiR-127 and miR-375 regulate the proliferation and differentiation of yak intramuscular adipocyte precursors through the toll-like receptor signaling pathway.","date":"2025","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/41387660","citation_count":0,"is_preprint":false},{"pmid":"41832493","id":"PMC_41832493","title":"Fibroblast-associated CTHRC1 as a key indicator of recurrence risk in prostate cancer.","date":"2026","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41832493","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16396,"output_tokens":2167,"usd":0.040847,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9240,"output_tokens":3103,"usd":0.061887,"stage2_stop_reason":"end_turn"},"total_usd":0.102734,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"IP6K3 (InsP6K3) was identified as a third inositol hexakisphosphate kinase that converts IP6 to InsP7 (diphosphoinositol pentakisphosphate). IP6K3 has a smaller mass (46 kDa) and more basic character than IP6K1/2, and its intracellular disposition was determined by fractionation: IP6K3 predominates in the cytoplasm, distinguishing it from the exclusively nuclear IP6K2 and the dual nuclear/cytosolic IP6K1.\",\n      \"method\": \"Enzyme activity assay (in vitro IP7 production), cellular fractionation, sequence analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic characterization combined with subcellular fractionation; foundational paper replicated in subsequent work\",\n      \"pmids\": [\"11502751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IP6K3 is highly concentrated in cerebellar Purkinje cells and physically interacts with the cytoskeletal proteins adducin and spectrin. In IP6K3-null mice, the adducin–spectrin interaction is perturbed, leading to abnormalities in Purkinje cell structure and synapse number, and deficits in motor learning and coordination.\",\n      \"method\": \"Co-immunoprecipitation (IP6K3 binding to adducin and spectrin), IP6K3 knockout mouse phenotype (cerebellar morphology, synapse counting, motor behavior tests)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus clean KO with defined structural and behavioral phenotypes in multiple assays\",\n      \"pmids\": [\"26245967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IP6K3 is enriched at the leading edge of migrating cells and physically associates with dynein intermediate chain 2 (DIC2). DIC2 and IP6K3 are recruited interdependently to the leading edge, where they cooperate to promote focal adhesion turnover. Deletion of IP6K3 causes defects in cell motility and neuronal dendritic growth, leading to brain malformations.\",\n      \"method\": \"Immunofluorescence microscopy, total internal reflection fluorescence (TIRF) microscopy, Co-immunoprecipitation (IP6K3–DIC2 interaction), IP6K3 knockout cells/mice with focal adhesion and motility assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, live TIRF imaging, and clean KO with multiple defined cellular and developmental phenotypes\",\n      \"pmids\": [\"30718399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic deletion of Ip6k3 in mice results in lower blood glucose, reduced circulating insulin, decreased fat mass, lower body weight, increased plasma lactate, enhanced glucose tolerance, improved insulin sensitivity, reduced muscle Pdk4 expression, and extended animal lifespan with concomitant reduced phosphorylation of S6 ribosomal protein in the heart, establishing IP6K3 as a regulator of metabolic homeostasis and longevity.\",\n      \"method\": \"Ip6k3 knockout mouse metabolic phenotyping (glucose tolerance test, insulin tolerance test, body composition, plasma metabolites, S6 phosphorylation by western blot)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with multiple metabolic readouts in a single lab; no independent replication reported\",\n      \"pmids\": [\"27577108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IP6K3 knockout reduces the size of the readily releasable pool (RRP) of synaptic vesicles containing both VGLUT1 and VGLUT2, and decreases synaptic facilitation at CA1 hippocampal Schaffer collateral synapses, whereas IP6K1 KO has the opposite effect on exocytosis. Both IP6K1 and IP6K3 KO similarly enhance endocytosis of VGLUT2-pHluorin after intense stimulation. IP6K3 is expressed in axons.\",\n      \"method\": \"IP6K3 knockout mice, live-cell imaging with pHluorin optical reporters (VGLUT1-pH, VGLUT2-pH), electrophysiology (CA1 field recordings), shRNA knockdown, pharmacological inhibition\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO plus electrophysiology and live imaging; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"35936490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The nuclear protein PA1 represses glucocorticoid receptor (GR)-mediated induction of the endogenous IP6K3 gene by blocking GR binding to the IP6K3 promoter, as demonstrated by ChIP and re-ChIP experiments, placing IP6K3 as a direct transcriptional target of GR regulated by the cofactor PA1.\",\n      \"method\": \"ChIP and re-ChIP at the IP6K3 promoter, luciferase reporter assays, endogenous gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP at endogenous locus in a single lab; establishes transcriptional regulation mechanism\",\n      \"pmids\": [\"23161582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A SNP (rs28607030) in the 5'-flanking promoter region of the IP6K3 gene affects IP6K3 promoter activity, with the G allele showing increased transcriptional activity as measured by luciferase assay, functionally linking promoter variation to altered IP6K3 expression levels.\",\n      \"method\": \"Luciferase reporter assay of IP6K3 promoter SNP variants\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single luciferase assay in a single lab; no additional mechanistic follow-up\",\n      \"pmids\": [\"27345265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Silencing of IP6K3 in calcifying primary human aortic vascular smooth muscle cells (VSMCs) produces some anti-calcific effects, suggesting a role in phosphate-induced VSMC calcification; however, IP6K3 mRNA expression was not modified under pro-calcific conditions, distinguishing IP6K3 from IP6K1/2 in this context.\",\n      \"method\": \"siRNA knockdown of IP6K3 in primary human aortic VSMCs, pro-calcific marker expression and calcification assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single knockdown experiment, single lab, partial mechanistic characterization without pathway placement for IP6K3 specifically\",\n      \"pmids\": [\"41683831\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IP6K3 is a cytoplasmic inositol hexakisphosphate kinase that converts IP6 to the inositol pyrophosphate 5-IP7; in the brain it is highly enriched in cerebellar Purkinje cells where it physically interacts with adducin and spectrin to regulate cytoskeletal organization, synapse formation, and motor learning, and at the leading edge of migrating cells it associates with dynein intermediate chain 2 (DIC2) to drive focal adhesion turnover and cell motility; systemically, its genetic deletion in mice improves glucose and lipid metabolism and extends lifespan, while in neurons it additionally controls synaptic vesicle pool size and exocytosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IP6K3 is a cytoplasmic inositol hexakisphosphate kinase that converts IP6 to the inositol pyrophosphate InsP7, distinguishing it from the nuclear IP6K2 and the dual-localized IP6K1 [#0]. Beyond this catalytic role, IP6K3 acts as a cytoskeleton-associated organizer in two distinct cellular contexts: it is enriched in cerebellar Purkinje cells where it physically binds adducin and spectrin, and its loss perturbs the adducin–spectrin interaction, distorting Purkinje cell structure and synapse number and impairing motor learning and coordination [#1]; and it concentrates at the leading edge of migrating cells where it associates interdependently with dynein intermediate chain 2 (DIC2) to drive focal adhesion turnover, with loss causing motility defects, impaired dendritic growth, and brain malformations [#2]. In neurons it additionally governs synaptic vesicle dynamics, with knockout reducing the readily releasable vesicle pool and synaptic facilitation at hippocampal Schaffer collateral synapses [#4]. Systemically, genetic deletion of Ip6k3 in mice improves glucose tolerance and insulin sensitivity, reduces fat mass, and extends lifespan, alongside reduced cardiac S6 phosphorylation, establishing IP6K3 as a regulator of metabolic homeostasis and longevity [#3]. Transcription of IP6K3 is a direct glucocorticoid receptor target repressed by the cofactor PA1, which blocks GR binding to the IP6K3 promoter [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that IP6K3 is a catalytically active third inositol hexakisphosphate kinase with a distinct subcellular distribution, defining it as a separate enzyme rather than a redundant copy of IP6K1/2.\",\n      \"evidence\": \"In vitro IP7 production assay, cellular fractionation, and sequence analysis\",\n      \"pmids\": [\"11502751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structural model of the catalytic site\",\n        \"Physiological substrate flux and InsP7 targets in vivo not defined\",\n        \"Functional consequence of cytoplasmic localization unresolved at this stage\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Answered how IP6K3 expression is controlled, showing it is a direct glucocorticoid receptor transcriptional target whose induction is repressed by the cofactor PA1.\",\n      \"evidence\": \"ChIP and re-ChIP at the endogenous IP6K3 promoter with luciferase reporter assays\",\n      \"pmids\": [\"23161582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological conditions driving GR-dependent IP6K3 induction unclear\",\n        \"Whether transcriptional regulation links to the metabolic phenotype untested\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the first physical partners and tissue-specific function of IP6K3, linking it to cytoskeletal organization in cerebellar Purkinje cells and to motor behavior.\",\n      \"evidence\": \"Reciprocal Co-IP with adducin and spectrin plus knockout mouse cerebellar morphology, synapse counting, and motor behavior assays\",\n      \"pmids\": [\"26245967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether IP6K3 catalytic activity (InsP7) is required for the adducin–spectrin effect not separated from a scaffolding role\",\n        \"Molecular basis of adducin/spectrin binding undefined\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that IP6K3 deletion improves systemic metabolism and extends lifespan, positioning IP6K3 as a regulator of metabolic homeostasis and aging.\",\n      \"evidence\": \"Ip6k3 knockout mouse metabolic phenotyping with glucose/insulin tolerance tests, body composition, plasma metabolites, and cardiac S6 phosphorylation\",\n      \"pmids\": [\"27577108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No independent replication reported\",\n        \"Tissue responsible for the metabolic/longevity phenotype not pinpointed\",\n        \"Mechanistic link between InsP7 and S6 signaling not established\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked a promoter SNP to IP6K3 expression level, providing a candidate basis for inter-individual variation in IP6K3 activity.\",\n      \"evidence\": \"Luciferase reporter assay comparing IP6K3 promoter SNP (rs28607030) variants\",\n      \"pmids\": [\"27345265\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single luciferase assay without endogenous validation\",\n        \"No demonstration of altered IP6K3 protein or phenotype in carriers\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a second cytoskeletal function for IP6K3 at the migrating cell leading edge through interdependent recruitment with DIC2 to drive focal adhesion turnover, connecting IP6K3 to motility and brain development.\",\n      \"evidence\": \"Immunofluorescence and TIRF microscopy, reciprocal Co-IP with DIC2, and knockout cell/mouse focal adhesion, motility, and dendritic growth assays\",\n      \"pmids\": [\"30718399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether InsP7 production is required for DIC2 cooperation untested\",\n        \"Relationship between the Purkinje adducin/spectrin role and the leading-edge DIC2 role unclear\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed that IP6K3 controls presynaptic vesicle dynamics, reducing the readily releasable pool and synaptic facilitation, with effects opposite to IP6K1 on exocytosis.\",\n      \"evidence\": \"Knockout mice with pHluorin live imaging (VGLUT1/VGLUT2), CA1 field electrophysiology, shRNA knockdown, and pharmacological inhibition\",\n      \"pmids\": [\"35936490\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular target of IP6K3/InsP7 at the synaptic vesicle cycle unidentified\",\n        \"Basis for opposing IP6K1 vs IP6K3 effects on exocytosis unexplained\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Implicated IP6K3 in phosphate-induced vascular smooth muscle calcification, distinguishing it from IP6K1/2 by its lack of transcriptional induction under pro-calcific conditions.\",\n      \"evidence\": \"siRNA knockdown of IP6K3 in primary human aortic VSMCs with calcification assays\",\n      \"pmids\": [\"41683831\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single knockdown experiment without rescue or independent confirmation\",\n        \"Pathway placement of IP6K3 in VSMC calcification not defined\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved whether IP6K3's diverse roles—cytoskeletal scaffolding, focal adhesion turnover, synaptic vesicle control, and metabolic regulation—depend on its InsP7 kinase activity or on activity-independent protein scaffolding, and which downstream effectors of InsP7 mediate each phenotype.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No catalytic-dead separation-of-function experiments reported across phenotypes\",\n        \"InsP7-dependent downstream effectors not identified for any tissue context\",\n        \"No structural data to connect catalysis with partner binding\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ADD1\",\n      \"SPTBN1\",\n      \"DYNC1I2\",\n      \"PA1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}